WOLF Grey Wolf Health Corp.
Grey Wolf Health Corp. operates as an animal health and wellness company in Canada. The company operates in two segments, Animal Health Business Unit and Pharmacy Business Unit. It engages in the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics, as well as offers pharmaceuticals for the human and animal health markets. The company provides dexmedetomidine hydrochloride oromucosal gel under the SILEO name; sedative analgesic and reversing agents for companion animals under the SEDAJECT and ATAJECT names; prescription drugs under the THYRO-TABS CANINE name; and wound care products, including medical grade tubes, viscose net dressings, alginate dressing, absorbent foam dressing, superabsorbent dressing, and silicone perforated tapes, as well as medical pet shirt protective wear products, such as pet shirt, pets boot, head cover, and leg sleeves. It also offers disposables comprising syringes, needles, and IV catheters; and nutraceuticals, as well as equine health products. The company was formerly known as Grey Wolf Animal Health Corp. and changed its name to Grey Wolf Health Corp. in June 2026. The company is headquartered in Toronto, Canada.…
Industry Peers
Pharmaceutical RetailersKey Statistics
About Grey Wolf Health (CVE: WOLF)
›
Grey Wolf Health (CVE: WOLF) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Pharmaceutical Retailers industry, part of the Healthcare sector.
The shares were at 1.500 CAD on 18 November 2026, up 25.0% over 52 weeks. Its 52-week range is 1.200 CAD to 1.850 CAD: the price is 18.9% below the high and 25.0% above the low.
At a market capitalisation of 51.96M CAD, it trades at 30.0 times trailing earnings and 30.0 times forward earnings. The median trailing P/E of its 4 largest Pharmaceutical Retailers peers is 25.0, a premium of 20% for WOLF.
Grey Wolf Health reports return on equity of 5.4%, an operating margin of 11.0% and revenue up 11.1% year over year.
Its debt exceeds its cash by 15.53M CAD, a debt-to-equity ratio of 0.83. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 2.250 CAD is 50.0% above the current price. The next earnings report is expected on 19 November 2026.